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compared to SAVR in elderly high risk patients, are very similar 
but better than medical treatment.(5) A recent review by the 
Canadian Agency for Drugs and Technology in Health 
(CADTH) of clinical durability and effectiveness of TAVI 
greater than 12 months, supported the use of TAVI and 
confirmed the similarity in outcomes to SAVR but cautioned 
that the robustness of the longer-term clinical efficacy data is 
still limited.(6) Of concern is the increased risk of major stroke 
or silent cerebral lesions in TAVI patients compared to 
SAVR(6-8) although a recent RCT comparing TAVI to SAVR in 
high-risk patients showed no difference in stroke outcome 
between the groups.(9) Currently SAVR remains the gold 
standard in patients who are good candidates for surgery.
In response to the introduction of TAVI in the South African 
private healthcare sector, a pilot study of eligible patients 
requiring TAVI was approved for funding by a large private 
healthcare insurer, in South Africa in 2010. Funding was initially 
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INTRODUCTION
Aortic stenosis (AS), the most common valvular heart disease, 
is a degenerative disease resulting from a progressive age-
dependent build-up of calcium that disrupts blood flow across 
the aortic valve. 
TAVI (Transcatheter aortic valve implantation) refers to an 
aortic valve replacement whereby the aortic valve is inserted 
percutaneously via the femoral artery (transfemoral), the aorta 
(transaortic) or via the left ventricle (transapical). TAVI is used 
to treat patients with symptomatic aortic stenosis who are 
unsuitable candidates for surgical replacement of the aortic 
valve (SAVR).(1,2)
Prior to 2010, the clinical evidence for TAVI was limited to 
feasibility and safety studies as well as observational data from 
the SOURCE Registry.(3) Data from the US Partner Trials 
(Partner A and Partner B) was published in 2010 and these 
were the first randomised controlled trials investigating surgical 
and medical management of aortic stenosis as well as com-
paring these treatment strategies to TAVI. The inclusion criteria 
for Partner B, in a cohort of 358 patients, were patients who 
were ineligible for surgical valve replacement.(2) Results showed 
that, compared to standard management (usually balloon valvu-
loplasty), the mortality rate was reduced by 20% in patients 
undergoing TAVI. At 24 months the mortality rate improve-
ment was 24.7% and patients undergoing TAVI had fewer 
re-hospitalisations (35%) compared to the standard treatment 
group (72.5%).(4) In the Partner A cohort longer term data (up 
to 30 months) showed that the clinical outcomes for TAVI, 
BACKGROUND: TAVI (Transcatheter aortic valve im-
plantation) is used to replace the aortic valve in the 
treatment of aortic stenosis in high-risk, elderly patients 
who are unable to undergo conventional surgical replace-
ment of the aortic valve (SAVR). However, concerns 
remain regarding the costs, long-term outcomes and 
safety of the device. A registry was developed by a 
healthcare funder to assess utilisation, outcomes and 
cost of this procedure in their patient population.
METHODS: Registry data was collected for a period of 
17 months. Clinical entry criteria included high-risk, 
elderly patients with symptomatic, severe aortic valve 
disease who were unsuitable for surgical valve replace-
ment. Clinical outcomes were mortality, readmission and 
pacemaker requirements post-surgery. Primary outcome 
measure was all-cause mortality at 30 days.
RESULTS: A cohort of 78 patients was enrolled, mean age 
of 79.53 years. Procedures were performed in 7 centers 
around the country. Thirty day all-cause mortality was 
9 (11.54%) with 5 deaths occurring on the day of the 
procedure. Eighteen (23.1%) patients were readmitted 
within 30 days. Average LOS was 5.71 (±4.06SD) days 
with an average cost of ZAR327 962 per patient.
CONCLUSION: Results suggest outcomes are similar to 
other settings and countries. Ongoing data collection is 
required to better understand long-term outcomes and 
costs.  SAHeart 2014;11:144-148 
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based on a model of a global fee of R365 000 which 
incorporated the hospital cost, the doctor’s fees, the TAVI 
valve and other in-hospital ancillary fees. Funding during the 
pilot (August 2010 - April 2012) was restricted to higher 
premium plan types and a co-payment was levied for the 
balance of the costs for the patient. Following the pilot, patients 
continued to be funded from the medical scheme benefit 
but the co-payment was removed from the higher plan types. 
A registry was implemented to collect data to inform further 
decision making around TAVI in this environment.
The aim of this study was to present the initial findings of 
the registry for TAVI patients and to assess whether outcomes 
and costs were comparable with other international registry 
experiences as well as in other South African settings.
In 2013 TAVI funding by the insurer was renegotiated, allow-
ing the Global Fee to be reset at R337 000. However, even 
at the current global fee, the TAVI procedure is significantly 
more expensive than medical management which is the 
alternative for patients who are not eligible for SAVR. It is 
important to note that there is no effective medical treatment 
for aortic stenosis. Contingent to making funding available were 
the agreements with the hospital groups, the South African 
Society of Cardiovascular Interventionists (SASCI) and the 
manufacturers of the TAVI valves as well as a commitment by 
stakeholders to measure outcomes including, amongst other 
parameters, mortality and pacemaker utilisation rates.
The extremely high cost of the valve is of particular concern 
in South Africa and it has not proven to be cost-effective in 
this setting. Cost-effectiveness analyses done in the United 
Kingdom,(10) USA(11) and Canada(12) from the Partner trial 
included a lifetime analysis with cost projections beyond the 12 
month trial period. The incremental cost-effectiveness ratio 
(ICER) outcomes of these studies suggested TAVI was cost-
effective, however the cost-effectiveness thresholds used in the 
different studies are reflective of willingness to pay in those 
countries and cannot necessarily be translated into a South 
African context. In the UK study, the cost-effectiveness out-
come was revised upwards from £16 100/QALY to £20 100/
QALY(13) (Watt (b), 2012) which places it on the cost-effec-
tiveness threshold limit. In the Canadian HTA study(12) the 
ICER was shown to be $48 912/QALY but with a range from 
$36 000/QALY to $291 000/QALY depending on the long-
term extrapolation assumptions made in the model. The USA 
economic assessment(11) estimated an ICER of $61 889/QALY 
in the PARTNER B patients.
The Edwards Lifesciences Sapien® Valve was the first TAVI 
valve to be introduced into the South African Market in 2010 
at a price of R216 000 (including VAT) per device. In 2011, 
the second TAVI valve, CoreValve®, from Medtronic was 
launched at a price of R188 177 (including VAT). This has since 
been revised to include other components and now costs 
R200 307.
METHODS
Data for insured patients enrolled on the TAVI Registry were 
collected from August 2010 - December 2013. Initially patients 
were funded as part of a pilot project from August 2010 - April 
2012. Following this, these patients continued to be tracked in 
the registry but were funded as part of the medical scheme 
benefits. Clinical entry criteria included only high-risk, elderly 
patients with symptomatic, severe degenerative aortic valve 
disease who were unsuitable for a surgical aortic valve replace-
ment. Selection of patients for the procedure was determined 
by the patient’s treating doctor(s) based on the SASCI 
treatment guidelines. For extraordinary cases an external panel 
of specialists was consulted. The choice of approach, either 
trans-apical or trans-femoral, was determined by the patient’s 
treating doctor(s). Patients were required to sign a consent 
form for the collection of data.
Data entry fields for the registry were categorised into Patient 
Demographics, Procedure Details, Costs and Outcomes. As 
this is a retrospective database review of an administrative 
claims database, the clinical outcomes measured were mortality, 
readmission and whether the patient required a pacemaker 
post-surgery as a result of the TAVI procedure. The primary 
outcome measure was all-cause mortality at 30 days. 
Costing data per patient was obtained from the claims database 
and included the global fee cost of the hospital admission 
(device, theatre time, hospital stay, doctor’s fees) as well as any 
additional radiology, pathology, physiotherapy or other costs 
incurred during the hospital admission. Where a pacemaker 
implantation was required, the cost of the pacemaker was 
recorded separately to the global fee. Based on the individual 
clinical merits of the case, patients on lower premium plans 
were also approved up to the cost of the open surgical 
procedure. Costs were adjusted to 2013 in South African Rand 
(R) using the Consumer Price Index (CPI) as published on the 
Statistics South Africa website (Stats SA).(14)
Patient data was obtained from the claims database, collated 
and analysed in an excel spreadsheet. Statistical analysis was 
carried out using STATA®.
RESULTS
Patient Demographics
A cohort of 78 patients was approved for funding for TAVI 
up until the end of December 2013. The first 42 patients 
were enrolled on the pilot (August 2010 - April 2012). The 
remaining patients (n=36) were also enrolled in the registry 
but were funded through a different funding benefit. The mean 
(±SD) age of patients undergoing TAVI was 79.53 (±6.75) 
years. The ratio of males to females was 48:30 (61.5%; 38.5%) 
(see Table 1). All patients were considered to be high risk and 
unable to tolerate a surgical aortic valve replacement.
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The procedures were performed at 7 centres around the 
country in 4 provinces (Gauteng, KwaZulu-Natal, Free State 
and Western Cape), see Figure 1. The majority of valves 
implanted were the Sapien® valve (76.9%) with only 23.1% of 
CoreValves® used to date. Since the introduction of the 
CoreValve® to the market in 2011, however, the proportion of 
Sapien® to CoreValves® used in the registry population has 
grown.
Clinical outcomes
The 30 day all cause mortality was 11.54% (9 patients) with 5 
deaths (7.2%) occurring on the same day as the procedure. 
Of the 42 patients in whom 1 year all cause mortality was 
measured, 14 patients (33.3%) died within 12 months of under-
going the procedure. There was an overall all-cause mortality 
rate of 21.79% (±0.41%) as measured in December 2013 in 
this patient population. The mortality rate for each year of the 
registry appears to be decreasing (Table 2.)
The average length of time from the TAVI procedure to death 
was 95 days. 
Hospital all-cause readmissions were counted as any admission 
post TAVI procedure. 23.1% of patients were readmitted 
within 30 days and of those readmissions, 5 were for com-
plications related to the procedure itself (Table 3). Twelve 
months following the initial event, 34.6% of patients had been 
readmitted one or more times.
Pacemaker requirements
Of the patients who received a TAVI, 7 (10.14%) required a 
pacemaker (either temporary or permanent). The frequency of 
pacemaker requirements decreased after the first year of the 
pilot from 4 used in the first year (August 2010 - July 2011), to 
3 used in the second year (August 2011 - July 2012) and none 
required in the current period (August 2012 - May 2013). Only 
2 of the pacemakers implanted were permanent.
Procedure costs
The average length of stay for patients admitted for a TAVI was 
5.71 (±4.06 SD) days with the maximum length of stay at 29 
days, however this did not include patients who were admitted, 
discharged and then readmitted the following day. The average 
length of stay from date of the TAVI procedure was 5.25 days.
Over the duration of the registry, more than R24.5 million has 
been paid towards the TAVI procedures, with a median cost of 
R329 722 (±56 354) per patient. In addition, a median cost of 
R8 047 per patient was paid towards claims for other services 
that were not covered under the global fee such as pathology, 
radiology and ancillary services.
DISCUSSION
The sample size of the patients enrolled in the pilot study was 
too small to carry out any meaningful statistical analysis. 
However, it does give a good indication of the expected 
outcomes in a South African private healthcare setting. These 
outcomes are not dissimilar to those reported in other 
international registries.
It is important to note that the majority of the pilot was carried 
out using the Sapien® valve and it was only in 2011 that the 
CoreValve® was introduced and reimbursed through the 
registry, hence the lower number of procedures and outcomes 
for that valve. The results of the registry analysis should 
therefore be considered with this in mind.
The 30 day all-cause mortality rate of 11.5% in this registry 
study was slightly higher than that reported in the Canadian 
registry study (10.4%),(15) in France(16) where rates of death at 
30 days and 1 year were 9.7 and 24.0% respectively and in 
China(17) with a 30 day all-cause mortality rate of 10.4%. In a 
study carried out in the Western Cape, South Africa, in 70 
patients using the Edwards Sapien® valve, the 30 day mortality 
rate was 7.1% with a procedural success rate of 97% (2 patients 
died during the procedure).(18) It appears that the 12 month 
mortality rate is declining with each successive year. This could 
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TABLE 1:  Baseline demographics.
 Total (n=78) Sapien® (n=60) CoreValve
®  
   (n=18)
Age (Mean) 79.53 years  79.76 78.72
 (±6.75) 
Male n (%) 48 (61.5) 35 (58.3) 13 (72.2)
FIGURE 1:  Breakdown of procedures by Province.
6.4%
55.1%
32.1%
6.4%
TAVI Procedures by Province
Western Cape         Gauteng         KwaZulu-Natal         Free State
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be due to reasons such as the result of better patient selection 
or increased familiarity with the procedure. 
The overall pacemaker implantation rate in this study was 
10.74% which is lower than other published rates. A recently 
published German Registry study analysing 1 391 patients 
undergoing TAVI, reported a pacemaker implantation rate of 
33.8% and 34.5% (NS) in patients who died or survived 
respectively.(19)
The readmission rate of 36% was not unexpected in the patient 
population undergoing valve replacement surgery. What was 
of interest was the number of non-cardiac related surgeries 
taking place following the TAVI procedure. This was presumably 
due to patients now being well enough to undergo planned 
procedures, such as hip replacements, that they could not have 
considered previously.
The median cost of R329 722 per patient is lower than the 
current global fee of R337 000 as not every patient claimed for 
the full amount. The global fee is a result of negotiations with 
the manufacturers, healthcare professionals and the hospitals to 
reduce their costs and this is reviewed on an annual basis in 
light of updated data and outcomes. The global fee is reflective 
of the funding strategy implemented by the insurer and is not 
necessarily an indication of the true costs of the procedure in a 
fee-for-service environment. Published data for TAVI costs in 
South Africa from an abstract in Eurointerven-tion(20) reported 
mean TAVI costs of R374 500 (±46 800) based on fee-for-
service charges. The average length of stay in hospital in that 
study was 7.7 days (2.8 days in ICU). A recently published 
analysis of the cost of TAVI in the same private hospital setting 
in South Africa showed similar results with mean TAVI costs of 
R335 500 (±47 900) although the length of stay was longer 
at 7.6 days.(21)
The cost of TAVI globally is often not clearly defined but 
reports in the literature vary from £16 500(22) to $70 000.(23) 
A recent review of re-imbursement for TAVI in Europe sug-
gests that uptake of the procedure varies depending on 
whether the funding is based on a TAVI-specific national DRG 
(reimbursed in full) as opposed to a constrained funding system 
(only partially funded or funded by local trust or hospital 
budget).(24)
Open heart surgery is still the gold standard for the treatment 
of aortic stenosis in patients who are eligible for surgery. TAVI 
has shown benefits in patients requiring aortic valve replace-
ment who are not candidates for surgical valve replacement, 
however long term outcomes are lacking. While the increased 
risk of harms (major stroke, cerebral lesions) associated with 
this procedure remains of concern, more recent trial data has 
shown that there is no difference in stroke outcomes in high-
risk patients undergoing TAVI or SAVR.(9) The cost of the valve 
and additional costs including hospitalisation, radiology and 
pathology, cardiologist, anesthetists and other health profes-
sionals involved in the procedure make TAVI an expensive 
procedure and, currently, of uncertain cost effectiveness. 
Affordability is of particular concern in the South African private 
sector setting. 
TABLE 2:  Mortality data for patients from August 2010 - September 2013.
Time period n (total patients) Deceased (by Dec 2013) %
08/2010 - 07/2011 27 9 33.3%
08/2011 - 07/2012 19 6 31.6%
08/2012 - 07/2013* 26 2 7.7%
Mortality Total (n=78) Sapien® (n=60) CoreValve® (n=18) p-value
30 day all cause n (%) 9 (11.54) 8 1 0.10*
1-year all cause n (%) 14/42 (33.3) - - NS
Overall all cause n (%) 17 (21.79) 16 (26.7) 1 (5.56) NS
Same day n (%) 5 4 1 NS
TABLE 3:  Hospital readmission data for patients from August 2010 - September 2013.
Readmissions Total no of events (n=78) Sapien® total events (n=60) CoreValve® total events (n=18)
All cause readmissions within 30 days 22 events (18 patients) 17 events (14 patients) 5 events (4 patients)
All cause readmissions within 12 months 42 events (27 patients) 26 events (16 patients) 16 events (8 patients)
Pacemakers 7 6 (10.9%) 1 (7.1%)
*  Fisher’s Exact test used to compare mortality in Sapien® vs. CoreValve® cohorts.
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The success of the TAVI story in this large health insurer has 
been in the commitment by all stakeholders to engage in 
making this procedure more affordable. This is an ongoing 
process as each year the clinical evaluation and funding decision 
is revisited to ensure TAVI is accessible to the most appropriate 
patient groups.
CONCLUSION
It is possible to measure outcomes of patients undergoing TAVI 
in a private healthcare setting based on database analysis. 
Results suggest outcomes are similar to other settings and 
countries. Ongoing data collection is required to better 
understand long-term outcomes and costs.
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